カテゴリ： 世界, 医療/バイオ, QYResearch

全身性アスペルギルス症/全身性カンジダ症治療の世界市場2023年：ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他

■ 英語タイトル：Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA7559）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA7559
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：96
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[全身性アスペルギルス症/全身性カンジダ症治療の世界市場2023年：ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は全身性アスペルギルス症/全身性カンジダ症治療のグローバル市場について調査・分析し、世界の全身性アスペルギルス症/全身性カンジダ症治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他）、用途別セグメント分析（慢性肺アスペルギルス症(CPA)、アレルギー性気管支肺アスペルギルス症(ABPA)、消化管カンジダ症、泌尿生殖器カンジダ症、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Basilea Pharmaceutica、Astellas Pharma、Ferrer International、Pacgen Life Science、NovaDigm Therapeutics、Cidara Therapeutics、Amplyx Pharmaceuticals、Pfizer、Novartis、Sanofi、Merck、Bayer、GlaxoSmithKline、Abbott、Ciplaなどが含まれています。全身性アスペルギルス症/全身性カンジダ症治療のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、全身性アスペルギルス症/全身性カンジダ症治療市場規模を算出する際に考慮しました。

・全身性アスペルギルス症/全身性カンジダ症治療市場の概要
- 全身性アスペルギルス症/全身性カンジダ症治療の種類別セグメント
- 世界の全身性アスペルギルス症/全身性カンジダ症治療市場規模：タイプ別分析（ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他）
- 全身性アスペルギルス症/全身性カンジダ症治療の用途別セグメント
- 世界の全身性アスペルギルス症/全身性カンジダ症治療市場規模：用途別分析（慢性肺アスペルギルス症(CPA)、アレルギー性気管支肺アスペルギルス症(ABPA)、消化管カンジダ症、泌尿生殖器カンジダ症、その他）
- 世界の全身性アスペルギルス症/全身性カンジダ症治療市場規模予測（2018年-2029年）

・全身性アスペルギルス症/全身性カンジダ症治療市場の成長トレンド
- 全身性アスペルギルス症/全身性カンジダ症治療の地域別市場規模（2018年-2029年）
- 全身性アスペルギルス症/全身性カンジダ症治療市場ダイナミクス
- 全身性アスペルギルス症/全身性カンジダ症治療の業界動向
- 全身性アスペルギルス症/全身性カンジダ症治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他
- 世界の全身性アスペルギルス症/全身性カンジダ症治療のタイプ別市場規模（2018年-2023年）
- 世界の全身性アスペルギルス症/全身性カンジダ症治療のタイプ別市場規模（2024年-2029年）

・用途別セグメント：慢性肺アスペルギルス症(CPA)、アレルギー性気管支肺アスペルギルス症(ABPA)、消化管カンジダ症、泌尿生殖器カンジダ症、その他
- 世界の全身性アスペルギルス症/全身性カンジダ症治療の用途別市場規模（2018年-2023年）
- 世界の全身性アスペルギルス症/全身性カンジダ症治療の用途別市場規模（2024年-2029年）

・全身性アスペルギルス症/全身性カンジダ症治療の地域別市場規模
- 北米の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- 米国の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- ヨーロッパの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- アジア太平洋の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- 中国の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- 日本の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- 韓国の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- インドの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- オーストラリアの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- 中南米の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）
- 中東・アフリカの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Basilea Pharmaceutica、Astellas Pharma、Ferrer International、Pacgen Life Science、NovaDigm Therapeutics、Cidara Therapeutics、Amplyx Pharmaceuticals、Pfizer、Novartis、Sanofi、Merck、Bayer、GlaxoSmithKline、Abbott、Cipla

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Systemic Aspergillosis and Systemic Candidiasis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Systemic Aspergillosis and Systemic Candidiasis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Systemic Aspergillosis and Systemic Candidiasis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Systemic Aspergillosis and Systemic Candidiasis Treatment in Chronic Pulmonary Aspergillosis (CPA) is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Systemic Aspergillosis and Systemic Candidiasis Treatment include Basilea Pharmaceutica, Astellas Pharma, Ferrer International, Pacgen Life Science, NovaDigm Therapeutics, Cidara Therapeutics, Amplyx Pharmaceuticals, Pfizer and Novartis, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Systemic Aspergillosis and Systemic Candidiasis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Aspergillosis and Systemic Candidiasis Treatment.
The Systemic Aspergillosis and Systemic Candidiasis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Systemic Aspergillosis and Systemic Candidiasis Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Systemic Aspergillosis and Systemic Candidiasis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Basilea Pharmaceutica
Astellas Pharma
Ferrer International
Pacgen Life Science
NovaDigm Therapeutics
Cidara Therapeutics
Amplyx Pharmaceuticals
Pfizer
Novartis
Sanofi
Merck
Bayer
GlaxoSmithKline
Abbott
Cipla
Segment by Type
Voriconazole
Liposomal Amphotericin B
Systemic Oral Azoles
Topical Antifungal Agents
Others
Segment by Application
Chronic Pulmonary Aspergillosis (CPA)
Allergic Bronchopulmonary Aspergillosis (ABPA)
Gastrointestinal Candidiasis
Genitourinary Tract Candidiasis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Systemic Aspergillosis and Systemic Candidiasis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Voriconazole
1.2.3 Liposomal Amphotericin B
1.2.4 Systemic Oral Azoles
1.2.5 Topical Antifungal Agents
1.2.6 Others
1.3 Market by Application
1.3.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Chronic Pulmonary Aspergillosis (CPA)
1.3.3 Allergic Bronchopulmonary Aspergillosis (ABPA)
1.3.4 Gastrointestinal Candidiasis
1.3.5 Genitourinary Tract Candidiasis
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Perspective (2018-2029)
2.2 Systemic Aspergillosis and Systemic Candidiasis Treatment Growth Trends by Region
2.2.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Systemic Aspergillosis and Systemic Candidiasis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Dynamics
2.3.1 Systemic Aspergillosis and Systemic Candidiasis Treatment Industry Trends
2.3.2 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Drivers
2.3.3 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Challenges
2.3.4 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Systemic Aspergillosis and Systemic Candidiasis Treatment Players by Revenue
3.1.1 Global Top Systemic Aspergillosis and Systemic Candidiasis Treatment Players by Revenue (2018-2023)
3.1.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue
3.4 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Concentration Ratio
3.4.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue in 2022
3.5 Systemic Aspergillosis and Systemic Candidiasis Treatment Key Players Head office and Area Served
3.6 Key Players Systemic Aspergillosis and Systemic Candidiasis Treatment Product Solution and Service
3.7 Date of Enter into Systemic Aspergillosis and Systemic Candidiasis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Systemic Aspergillosis and Systemic Candidiasis Treatment Breakdown Data by Type
4.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Type (2024-2029)
5 Systemic Aspergillosis and Systemic Candidiasis Treatment Breakdown Data by Application
5.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Historic Market Size by Application (2018-2023)
5.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
6.2 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
6.4 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
7.2 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
7.4 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
9.2 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
9.4 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Basilea Pharmaceutica
11.1.1 Basilea Pharmaceutica Company Detail
11.1.2 Basilea Pharmaceutica Business Overview
11.1.3 Basilea Pharmaceutica Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.1.4 Basilea Pharmaceutica Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.1.5 Basilea Pharmaceutica Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Detail
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.2.4 Astellas Pharma Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.2.5 Astellas Pharma Recent Development
11.3 Ferrer International
11.3.1 Ferrer International Company Detail
11.3.2 Ferrer International Business Overview
11.3.3 Ferrer International Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.3.4 Ferrer International Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.3.5 Ferrer International Recent Development
11.4 Pacgen Life Science
11.4.1 Pacgen Life Science Company Detail
11.4.2 Pacgen Life Science Business Overview
11.4.3 Pacgen Life Science Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.4.4 Pacgen Life Science Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.4.5 Pacgen Life Science Recent Development
11.5 NovaDigm Therapeutics
11.5.1 NovaDigm Therapeutics Company Detail
11.5.2 NovaDigm Therapeutics Business Overview
11.5.3 NovaDigm Therapeutics Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.5.4 NovaDigm Therapeutics Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.5.5 NovaDigm Therapeutics Recent Development
11.6 Cidara Therapeutics
11.6.1 Cidara Therapeutics Company Detail
11.6.2 Cidara Therapeutics Business Overview
11.6.3 Cidara Therapeutics Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.6.4 Cidara Therapeutics Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.6.5 Cidara Therapeutics Recent Development
11.7 Amplyx Pharmaceuticals
11.7.1 Amplyx Pharmaceuticals Company Detail
11.7.2 Amplyx Pharmaceuticals Business Overview
11.7.3 Amplyx Pharmaceuticals Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.7.4 Amplyx Pharmaceuticals Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.7.5 Amplyx Pharmaceuticals Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.8.4 Pfizer Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.9.4 Novartis Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.9.5 Novartis Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.10.4 Sanofi Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.10.5 Sanofi Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.11.4 Merck Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.11.5 Merck Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.12.4 Bayer Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.12.5 Bayer Recent Development
11.13 GlaxoSmithKline
11.13.1 GlaxoSmithKline Company Detail
11.13.2 GlaxoSmithKline Business Overview
11.13.3 GlaxoSmithKline Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.13.4 GlaxoSmithKline Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.13.5 GlaxoSmithKline Recent Development
11.14 Abbott
11.14.1 Abbott Company Detail
11.14.2 Abbott Business Overview
11.14.3 Abbott Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.14.4 Abbott Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.14.5 Abbott Recent Development
11.15 Cipla
11.15.1 Cipla Company Detail
11.15.2 Cipla Business Overview
11.15.3 Cipla Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.15.4 Cipla Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.15.5 Cipla Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Voriconazole
Table 3. Key Players of Liposomal Amphotericin B
Table 4. Key Players of Systemic Oral Azoles
Table 5. Key Players of Topical Antifungal Agents
Table 6. Key Players of Others
Table 7. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Region (2018-2023)
Table 11. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Region (2024-2029)
Table 13. Systemic Aspergillosis and Systemic Candidiasis Treatment Market Trends
Table 14. Systemic Aspergillosis and Systemic Candidiasis Treatment Market Drivers
Table 15. Systemic Aspergillosis and Systemic Candidiasis Treatment Market Challenges
Table 16. Systemic Aspergillosis and Systemic Candidiasis Treatment Market Restraints
Table 17. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Players (2018-2023)
Table 19. Global Top Systemic Aspergillosis and Systemic Candidiasis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment as of 2022)
Table 20. Ranking of Global Top Systemic Aspergillosis and Systemic Candidiasis Treatment Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Systemic Aspergillosis and Systemic Candidiasis Treatment Product Solution and Service
Table 24. Date of Enter into Systemic Aspergillosis and Systemic Candidiasis Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue Market Share by Type (2018-2023)
Table 28. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue Market Share by Type (2024-2029)
Table 30. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue Market Share by Application (2018-2023)
Table 32. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue Market Share by Application (2024-2029)
Table 34. North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 49. Basilea Pharmaceutica Company Detail
Table 50. Basilea Pharmaceutica Business Overview
Table 51. Basilea Pharmaceutica Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 52. Basilea Pharmaceutica Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 53. Basilea Pharmaceutica Recent Development
Table 54. Astellas Pharma Company Detail
Table 55. Astellas Pharma Business Overview
Table 56. Astellas Pharma Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 57. Astellas Pharma Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 58. Astellas Pharma Recent Development
Table 59. Ferrer International Company Detail
Table 60. Ferrer International Business Overview
Table 61. Ferrer International Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 62. Ferrer International Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 63. Ferrer International Recent Development
Table 64. Pacgen Life Science Company Detail
Table 65. Pacgen Life Science Business Overview
Table 66. Pacgen Life Science Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 67. Pacgen Life Science Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 68. Pacgen Life Science Recent Development
Table 69. NovaDigm Therapeutics Company Detail
Table 70. NovaDigm Therapeutics Business Overview
Table 71. NovaDigm Therapeutics Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 72. NovaDigm Therapeutics Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 73. NovaDigm Therapeutics Recent Development
Table 74. Cidara Therapeutics Company Detail
Table 75. Cidara Therapeutics Business Overview
Table 76. Cidara Therapeutics Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 77. Cidara Therapeutics Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 78. Cidara Therapeutics Recent Development
Table 79. Amplyx Pharmaceuticals Company Detail
Table 80. Amplyx Pharmaceuticals Business Overview
Table 81. Amplyx Pharmaceuticals Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 82. Amplyx Pharmaceuticals Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 83. Amplyx Pharmaceuticals Recent Development
Table 84. Pfizer Company Detail
Table 85. Pfizer Business Overview
Table 86. Pfizer Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 87. Pfizer Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 88. Pfizer Recent Development
Table 89. Novartis Company Detail
Table 90. Novartis Business Overview
Table 91. Novartis Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 92. Novartis Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 93. Novartis Recent Development
Table 94. Sanofi Company Detail
Table 95. Sanofi Business Overview
Table 96. Sanofi Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 97. Sanofi Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 98. Sanofi Recent Development
Table 99. Merck Company Detail
Table 100. Merck Business Overview
Table 101. Merck Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 102. Merck Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 103. Merck Recent Development
Table 104. Bayer Company Detail
Table 105. Bayer Business Overview
Table 106. Bayer Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 107. Bayer Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 108. Bayer Recent Development
Table 109. GlaxoSmithKline Company Detail
Table 110. GlaxoSmithKline Business Overview
Table 111. GlaxoSmithKline Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 112. GlaxoSmithKline Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 113. GlaxoSmithKline Recent Development
Table 114. Abbott Company Detail
Table 115. Abbott Business Overview
Table 116. Abbott Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 117. Abbott Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 118. Abbott Recent Development
Table 119. Cipla Company Detail
Table 120. Cipla Business Overview
Table 121. Cipla Systemic Aspergillosis and Systemic Candidiasis Treatment Product
Table 122. Cipla Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023) & (US$ Million)
Table 123. Cipla Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Type: 2022 VS 2029
Figure 3. Voriconazole Features
Figure 4. Liposomal Amphotericin B Features
Figure 5. Systemic Oral Azoles Features
Figure 6. Topical Antifungal Agents Features
Figure 7. Others Features
Figure 8. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Application: 2022 VS 2029
Figure 10. Chronic Pulmonary Aspergillosis (CPA) Case Studies
Figure 11. Allergic Bronchopulmonary Aspergillosis (ABPA) Case Studies
Figure 12. Gastrointestinal Candidiasis Case Studies
Figure 13. Genitourinary Tract Candidiasis Case Studies
Figure 14. Others Case Studies
Figure 15. Systemic Aspergillosis and Systemic Candidiasis Treatment Report Years Considered
Figure 16. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Region: 2022 VS 2029
Figure 19. Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Players in 2022
Figure 20. Global Top Systemic Aspergillosis and Systemic Candidiasis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue in 2022
Figure 22. North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Country (2018-2029)
Figure 24. United States Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Country (2018-2029)
Figure 28. Germany Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Region (2018-2029)
Figure 36. China Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Japan Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. South Korea Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Southeast Asia Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. India Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Australia Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Country (2018-2029)
Figure 44. Mexico Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Brazil Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Country (2018-2029)
Figure 48. Turkey Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Saudi Arabia Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Basilea Pharmaceutica Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 51. Astellas Pharma Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 52. Ferrer International Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 53. Pacgen Life Science Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 54. NovaDigm Therapeutics Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 55. Cidara Therapeutics Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 56. Amplyx Pharmaceuticals Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 57. Pfizer Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 58. Novartis Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 59. Sanofi Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 60. Merck Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 61. Bayer Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 63. Abbott Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 64. Cipla Revenue Growth Rate in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 全身性アスペルギルス症及び全身性カンジダ症治療のグローバル市場展望 2023年-2029年：ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他
  • 渓谷熱治療薬の世界市場2023年：フルコナゾール、ボリコナゾール、ポサコナゾール、アムホテリシンB、その他
  • トリメチルアミン尿症治療の世界市場2023年：経口、注射
  • 潰瘍性大腸炎治療オプションの世界市場2023年：抗炎症薬、免疫抑制剤、その他医薬品
  • 子宮内膜症治療薬の世界市場2023年：ホルモン避妊薬、プロゲステロン補充療法、GnRHAアナログ
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA7559 )"全身性アスペルギルス症/全身性カンジダ症治療の世界市場2023年：ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他" (英文：Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。